Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Menu

Metoprolol Succinate ER 100Mg Tabs 100 By Actavis Pharma

Image 0 of Metoprolol Succinate ER 100Mg Tabs 100 By Actavis PharmaImage 1 of Metoprolol Succinate ER 100Mg Tabs 100 By Actavis Pharma

Metoprolol Succinate ER 100Mg Tabs 100 By Actavis Pharma

Call for Price

Metoprolol Succinate ER 100Mg Tabs 100 By Actavis Pharma This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXD4302774/RXB10010887
Size : 100
Selling UoM : EA
NDC: 62037-0832-01
UPC Barcode : 362037832017
Supplier: 0050000679 ACTAVIS PHARMA INC/GENERIC
Supplier Material : 083201
Generic Code : 016600 METOPROLOL SUCCINATE ORAL TAB ER 24H 100
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : GR

Have a question?

  Call for Price

Product Description.:

Logo and 832
tablet , coated , white , scored , round round
Debossed

TOPROL-XL, metoprolol succinate, is a beta1-selective (cardioselective) adrenoceptor blocking agent, for oral administration, available as extended release tablets. TOPROL-XL has been formulated to provide a controlled and predictable release of metoprolol for once-daily administration. The tablets comprise a multiple unit system containing metoprolol succinate in a multitude of controlled release pellets. Each pellet acts as a separate drug delivery unit and is designed to deliver metoprolol continuously over the dosage interval. The tablets contain 23.75, 47.5, 95 and 190 mg of metoprolol succinate equivalent to 25, 50, 100 and 200 mg of metoprolol tartrate, USP, respectively.

Metoprolol succinate is a white crystalline powder with a molecular weight of 652.8. It is freely soluble in water soluble in methanol sparingly soluble in ethanol slightly soluble in dichloromethane and 2-propanol practically insoluble in ethyl-acetate, acetone, diethylether and heptane. Inactive ingredients: silicon dioxide, cellulose compounds, sodium stearyl fumarate, polyethylene glycol, titanium dioxide, paraffin.

INDICATIONS

Hypertension
TOPROL-XL is indicated for the treatment of hypertension. It may be used alone or in combination with other antihypertensive agents

Angina Pectoris

TOPROL-XL is indicated in the long-term treatment of angina pectoris, to reduce angina attacks and to improve exercise tolerance.
Heart Failure

TOPROL-XL is indicated for the treatment of stable, symptomatic (NYHA Class II or III) heart failure of ischemic, hypertensive, or cardiomyopathic origin. It was studied in patients already receiving ACE inhibitors, diuretics, and, in the majority of cases, digitalis. In this population, TOPROL-XL decreased the rate of mortality plus hospitalization, largely through a reduction in cardiovascular mortality and hospitalizations for heart failure.

WARNINGS

Included as part of the PRECAUTIONS section.
PRECAUTIONS
Ischemic Heart Disease

Following abrupt cessation of therapy with certain beta-blocking agents, exacerbations of angina pectoris and, in some cases, myocardial infarction have occurred. When discontinuing chronically administered TOPROL-XL, particularly in patients with ischemic heart disease gradually reduce the dosage over a period of 1 - 2 weeks and monitor the patient. If angina markedly worsens or acute coronary ischemia develops, promptly reinstate TOPROL-XL, and take measures appropriate for the management of unstable angina. Warn patients not to interrupt therapy without their physician's advice. Because coronary artery disease is common and may be unrecognized, avoid abruptly discontinuing TOPROL-XL in patients treated only for hypertension.
Heart Failure

Worsening cardiac failure may occur during up-titration of TOPROL-XL. If such symptoms occur, increase diuretics and restore clinical stability before advancing the dose of TOPROLXL [see DOSAGE AND ADMINISTRATION]. It may be necessary to lower the dose of TOPROLXL or temporarily discontinue it. Such episodes do not preclude subsequent successful titration of TOPROL-XL.
Bronchospastic Disease

PATIENTS WITH BRONCHOSPASTIC DISEASES SHOULD, IN GENERAL, NOT RECEIVE BETA-BLOCKERS. Because of its relative beta1 cardio-selectivity, however, TOPROL-XL may be used in patients with bronchospastic disease who do not respond to, or cannot tolerate, other antihypertensive treatment. Because beta1-selectivity is not absolute, use the lowest possible dose of TOPROL-XL. Bronchodilators, including beta2-agonists, should be readily available or administered concomitantly